Abstract
We discuss some issues in using quality of life endpoints in studies that will lead to an application to license a product or add an indication to an already licensed product. Studies of this sort should be double blinded, randomized and use validated questionnaires. The duration of the study should be appropriate for the indication. Missing values can be a serious problem and plans for handling them should be included. Sensitivity analyses are important in this context. An example of a sensitivity analysis shows how substitutions for missing values can offer insight into the effect of these missing values. An alternative model is given to analyze data of this sort. Other analytic methods are discussed in the second part of the paper. The views and opinions expressed in this paper are those of the authors and do not necessarily represent those of the Food and Drug Administration.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Berkanovic, E. and Hurwicz, M.L. (1990). Rheumatoid arthritis and comorbidity. Journal of Rheumatology 17, 888–892.
DeMetri, G.D., Kris, M., Wade, J., Degos, L. and Cella, D. (1998). Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: results from a prospective community oncology study. Journal of Clinical Oncology 16, 3412–3425.
Hurwicz, M.L. and Berkanovic, E. (1993). The stress process in rheumatoid arthritis. Journal of Rheumatology 20, 1836–1844.
Lachenbruch, P.A. (2000). Comparisons of two-part models with competitors. Statistics in Medicine 20, 1215–1234.
Little, R.J.A. (1993). Pattern mixture models for multivariate incomplete data. Journal of the American Statistical Association 88, 125–134.
Little, R.J.A. (1995). Modeling the drop-out mechanism in repeated-measures studies. Journal of the American Statistical Association 90, 1112–1121.
Schluchter, M.D. (1992). Methods for the analysis of informatively censored longitudinal data. Statistics in Medicine 11, 1861–1870.
Staquet, M.J., Hays, R.D. and Fayers, P.M., eds. (1998). Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press.
Zeger, S.L., Liang, K.Y. and Albert, P.S. (1988). Models for longitudinal data: a generalized estimating equations approach. Biometrics 44, 1049–1060.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Gnecco, C., Lachenbruch, P.A. (2002). Regulatory Aspects of Quality of Life. In: Mesbah, M., Cole, B.F., Lee, ML.T. (eds) Statistical Methods for Quality of Life Studies. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3625-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3625-0_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-5207-3
Online ISBN: 978-1-4757-3625-0
eBook Packages: Springer Book Archive